Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Agenus Inc (NASDAQ:AGEN)

3.91
Delayed Data
As of 4:00pm ET
 -0.29 / -6.90%
Today’s Change
2.61
Today|||52-Week Range
9.64
-13.88%
Year-to-Date
Better Buy: Agenus Inc. vs. bluebird bio
8:10am / MotleyFool.com - Paid Partner Content
Should Pfizer Buy This Beaten-Down Immuno-Oncology Company?
Jun 14 / MotleyFool.com - Paid Partner Content
Agenus Charts Shows Upside Potential
Jun 20 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close4.20
Today’s open3.85
Day’s range3.82 - 4.08
Volume1,412,095
Average volume (3 months)1,148,551
Market cap$363.4M
Dividend yield--
Data as of 4:00pm ET, 06/24/2016

Growth & Valuation

Earnings growth (last year)-59.15%
Earnings growth (this year)-25.07%
Earnings growth (next 5 years)+1.00%
Revenue growth (last year)+255.67%
P/E ratioNM
Price/Sales14.31
Price/Book5.13

Competitors

 Today’s
change
Today’s
% change
NDRMNeuroderm Ltd-0.75-4.45%
CGENCompugen Ltd-0.32-4.57%
ESPREsperion Therapeutic...-0.78-4.62%
VYGRVoyager Therapeutics...+0.01+0.08%
Data as of 4:00pm ET, 06/24/2016

Financials

Next reporting dateJuly 21, 2016
EPS forecast (this quarter)-$0.35
Annual revenue (last year)$24.8M
Annual profit (last year)-$87.9M
Net profit margin-354.12%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Garo H. Armen
Chief Financial Officer
Charles Evan Ballantyne
Corporate headquarters
Lexington, Massachusetts

Forecasts

Partner Offers

Search for Jobs